Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)

Cantor Fitzgerald analyst Kristen Kluska reiterated a Neutral rating and $14.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

The analyst commented, "SRPT reported that the FDA notified the company that it may lift the voluntary pause of ELEVIDYS shipment for ambulatory DMD patients. The decision follows the FDA’s review of the death of an 8-year-old ELEVIDYS patient in Brazil, which was determined to be unlikely related to the therapy. The stock is up ~48% after market off of the backs of this news… This theoretically removes the worst-case scenario on the stock, as even though we believe sales will decline, the company will still be able to generate ELEVIDYS revenues towards its convertible notes and pay ARWR (OW - Agrawal) its owed milestones."

For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.

Shares of Sarepta Therapeutics closed at $13.86 yesterday.

You May Also Be Interested In

• Belite Bio, Inc, ADR (BLTE) PT Raised to $220 at Mizuho
• Mizuho Reiterates Outperform Rating on SpaceX (SPCX)
• Wedbush Downgrades Globant S.A. (GLOB) to Neutral on balanced risk/reward